Activation of the KRAS oncogene has been implicated in colorectal carcinogenesis, being mutated in 30–40% of adenocarcinomas [5]–[8], a prevalence comparable to that observed in the present study (42.85%). The gene discussed is KRAS; the disease is adenocarcinoma.